Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer

Nikki Martin Headshot
Interview
Adopting Reflex Biomarker Testing to Improve Clinical Workflows for Patients With Non–Small Cell Lung Cancer
09/18/2026
Nikki Martin, MA
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin,...
09/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part II
08/18/2026
Kelsey Pan, MD
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses...
08/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part I
08/18/2026
Kelsey Pan, MD
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan,...
08/18/2026
Journal of Clinical Pathways
News
Liquid Biopsies Show Promise but Face Key Challenges in Older Adults
04/29/2026
Lisa Kuhns, PhD, MD
Liquid biopsies hold promise for transforming cancer care in older adults—but age-related biological changes may complicate their accuracy and clinical use.
Liquid biopsies hold promise for transforming cancer care in older adults—but age-related biological changes may complicate their accuracy and clinical use.
Liquid biopsies hold promise for...
04/29/2026
Journal of Clinical Pathways
News
Pharmacist Interventions in The US Oncology Network Cut Cancer Care Costs by Nearly $9 Million
11/17/2025
Grace Taylor, MS, MA
Pharmacist-led interventions within The US Oncology Network cut nearly $9 million in cancer care costs, showcasing the power of targeted medication management in value-based oncology care.
Pharmacist-led interventions within The US Oncology Network cut nearly $9 million in cancer care costs, showcasing the power of targeted medication management in value-based oncology care.
Pharmacist-led interventions...
11/17/2025
Journal of Clinical Pathways
Conference Coverage
Patient-Centered Insights into Treatment Preferences for Locally Advanced and Metastatic NSCLC
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
News
Radiomics and AI Advance NSCLC Staging Precision
03/10/2025
Juliet Gallagher
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in...
03/10/2025
Journal of Clinical Pathways
News
Machine Learning Identifies Key Genomic Markers to Predict CPI Outcomes in NSCLC
03/06/2025
Grace Taylor, MS, MA
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study...
03/06/2025
Journal of Clinical Pathways
News
Evaluating Cost-Effectiveness of First-Line Cemiplimab Therapy in Advanced NSCLC
03/05/2025
Juliet Gallagher
A recent cost-effectiveness analysis published in Journal of Managed Care & Specialty Pharmacy comparing cemiplimab plus chemotherapy (CCT) with pembrolizumab plus chemotherapy (PCT) as first-line treatment for advanced non-small cell lung...
A recent cost-effectiveness analysis published in Journal of Managed Care & Specialty Pharmacy comparing cemiplimab plus chemotherapy (CCT) with pembrolizumab plus chemotherapy (PCT) as first-line treatment for advanced non-small cell lung...
A recent cost-effectiveness...
03/05/2025
Journal of Clinical Pathways
News
Durvalumab Immunotherapy Shows Survival Benefit but Fails Cost-Effectiveness in Key Markets
02/13/2025
Lisa Kuhns, PhD, MD
Durvalumab immunotherapy improves survival in unresectable stage III non-small cell lung cancer (NSCLC), but its high cost makes it prohibitive globally under current pricing models, according to study results published in JAMA Network Open.
Durvalumab immunotherapy improves survival in unresectable stage III non-small cell lung cancer (NSCLC), but its high cost makes it prohibitive globally under current pricing models, according to study results published in JAMA Network Open.
Durvalumab immunotherapy...
02/13/2025
Journal of Clinical Pathways
News
Machine Learning Algorithms Offer Alternative to Imaging in NSCLC Staging
02/03/2025
Juliet Gallagher
A recent study published in Journal of Thoracic Disease demonstrated the effectiveness of artificial intelligence (AI) in predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC).
A recent study published in Journal of Thoracic Disease demonstrated the effectiveness of artificial intelligence (AI) in predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC).
A recent study published in...
02/03/2025
Journal of Clinical Pathways

Expert Insights

Nikki Martin Headshot
Interview
Adopting Reflex Biomarker Testing to Improve Clinical Workflows for Patients With Non–Small Cell Lung Cancer
09/18/2026
Nikki Martin, MA
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin,...
09/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part II
08/18/2026
Kelsey Pan, MD
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses...
08/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part I
08/18/2026
Kelsey Pan, MD
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan,...
08/18/2026
Journal of Clinical Pathways
Sarah Smith, Virginia Cancer Specialists
Videos
Post-Progression and Safety Outcomes With First-Line Amivantamab Plus Lazertinib vs Osimertinib for Advanced NSCLC: Best Management Practices
05/24/2024
Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...
Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...
Sarah Smith, BD, CNMT, discusses...
05/24/2024
Oncology
David Waterhouse, MD.
Videos
Increasing Biomarker Testing Rates for Patients With NSCLC
12/07/2023
David Waterhouse, MD, MPH
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.
David Waterhouse, MD, MPH, talks...
12/07/2023
Journal of Clinical Pathways
Thomas Stricker, MD.
Videos
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer
07/12/2023
Thomas Stricker, MD
Thomas Stricker, MD, PhD, speaks with the Journal of Clinical Pathways about his research on the clinical impact of the timing of first line targeted therapy in aNSCLC patients with actionable driver oncogenes.
Thomas Stricker, MD, PhD, speaks with the Journal of Clinical Pathways about his research on the clinical impact of the timing of first line targeted therapy in aNSCLC patients with actionable driver oncogenes.
Thomas Stricker, MD, PhD, speaks...
07/12/2023
Journal of Clinical Pathways
Janet Espirito, PharmD.
Videos
Real-World Response Endpoints in Patients With mNSCLC Treated With Chemotherapy Across Real-World Datasets
07/03/2023
Janet Espirito, PharmD
Janet L. Espirito, PharmD, Senior Medical Director for Ontada, speaks with the Journal of Clinical Pathways about the significance of her research on real-world response endpoints in patients with mNSCLC treated with chemotherapy across...
Janet L. Espirito, PharmD, Senior Medical Director for Ontada, speaks with the Journal of Clinical Pathways about the significance of her research on real-world response endpoints in patients with mNSCLC treated with chemotherapy across...
Janet L. Espirito, PharmD,...
07/03/2023
Journal of Clinical Pathways
Gregory Vidal, MD, Phd
Conference Coverage
Inequities in Next-Generation Sequencing Testing Among Patients With Advanced Non–Small Cell Lung Cancer
06/07/2023
Dr Gregory Vidal, Breast Medical Oncologist, West Cancer Center, Germantown, TN, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about his study on inequities in next-generation sequencing testing by race/ethnicity...
Dr Gregory Vidal, Breast Medical Oncologist, West Cancer Center, Germantown, TN, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about his study on inequities in next-generation sequencing testing by race/ethnicity...
Dr Gregory Vidal, Breast Medical...
06/07/2023
Journal of Clinical Pathways
Tejas Patil, MD, University of Colorado Cancer Center
Videos
Utilizing Clinical Pathways in the Treatment of Patients With ALK-Positive NSCLC
04/14/2023
Tejas Patil, MD, University of Colorado Cancer Center, discusses recent developments in the treatment landscape for patients with ALK-positive NSCLC and how clinical pathways can help standardize the treatment practices for these patients.
Tejas Patil, MD, University of Colorado Cancer Center, discusses recent developments in the treatment landscape for patients with ALK-positive NSCLC and how clinical pathways can help standardize the treatment practices for these patients.
Tejas Patil, MD, University of...
04/14/2023
Journal of Clinical Pathways
Janet Espirito, PharmD
Videos
Integrating Biomarker Testing Into Clinical Pathways to Optimize the NSCLC Treatment Landscape
11/03/2022
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD, discusses the importance of education, awareness of technology, and support for providers and patients to utilize comprehensive testing so that patients can receive the proper treatment at the right time.
Janet Espirito, PharmD,...
11/03/2022
Journal of Clinical Pathways
Nikki Martin Headshot
Interview
Adopting Reflex Biomarker Testing to Improve Clinical Workflows for Patients With Non–Small Cell Lung Cancer
09/18/2026
Nikki Martin, MA
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin, MA, discusses the benefits of comprehensive biomarker testing for patients with newly diagnosed non–small cell lung cancer (NSCLC), explaining how it can streamline decision-making processes, improve clinical...
In this interview, Nikki Martin,...
09/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part II
08/18/2026
Kelsey Pan, MD
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses evolving approaches to managing treatment resistance in non-small cell lung cancer, barriers to equitable precision oncology, and emerging targeted therapies that may shape future treatment strategies.
A guest expert discusses...
08/18/2026
Journal of Clinical Pathways
Kelsey Pan Headshot
Interview
Navigating Biomarker-Driven Treatment in Advanced NSCLC: Part I
08/18/2026
Kelsey Pan, MD
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan, MD, MPH, discusses how biomarker testing and emerging targeted therapies are reshaping treatment selection, resistance management, and precision oncology in advanced non–small cell lung cancer (NSCLC).
In this interview, Kelsey Pan,...
08/18/2026
Journal of Clinical Pathways
Deirdre Saulet, PhD
Blog
How AI, Data, and Real-World Evidence Are Transforming Oncology Clinical Pathways
07/14/2026
Deirdre Saulet, PhD
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026 will bring together oncology leaders to explore practical strategies for using technology to build smarter, more responsive clinical pathways that improve care delivery.
Clinical Pathways Congress 2026...
07/14/2026
Journal of Clinical Pathways
B-cell lymphoma
Videos
Dual-Targeting CAR T-Cell Therapy: Implications for Relapsed or Refractory Large B-Cell Lymphoma
07/06/2026
Paolo Strati, MD
Paolo Strati, MD, discusses how findings from the ZUMA-14 trial could shape the future of dual-targeting CAR T-cell therapy, treatment sequencing, and minimal residual disease monitoring in relapsed or refractory large B-cell lymphoma.
Paolo Strati, MD, discusses how findings from the ZUMA-14 trial could shape the future of dual-targeting CAR T-cell therapy, treatment sequencing, and minimal residual disease monitoring in relapsed or refractory large B-cell lymphoma.
Paolo Strati, MD, discusses how...
07/06/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis: Part 2
06/19/2026
Rahul Mudumba, PhD, MHS
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how...
06/19/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis
06/18/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how...
06/18/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration: Part 2
06/17/2026
Kishen Patel, PharmD
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores how integrated specialty pharmacy services are helping health systems reduce acute care utilization, strengthen oncology pathways, and demonstrate the long-term value of pharmacist-led care.
Kishen Patel, PharmD, explores...
06/17/2026
Journal of Clinical Pathways
Specialty Pharmacy, Clinical Pathways, Oncology
Videos
Building Better Oncology Pathways With Specialty Pharmacy Integration
06/17/2026
Kishen Patel, PharmD
In this interview, Kishen Patel, PharmD, discusses how pharmacist-led interventions and integrated specialty pharmacy services can improve adherence, address treatment barriers, and support better outcomes for patients receiving oral oncology...
In this interview, Kishen Patel, PharmD, discusses how pharmacist-led interventions and integrated specialty pharmacy services can improve adherence, address treatment barriers, and support better outcomes for patients receiving oral oncology...
In this interview, Kishen Patel,...
06/17/2026
Journal of Clinical Pathways
DLBCL, Diffuse Large B-Cell Lymphoma
Interview
Cardiopulmonary Comorbidities and CRS Risk After CAR T-Cell Therapy in DLBCL: Insights From Real-World Data
06/11/2026
Heidi Cho, MD
Real-world data suggest that common cardiac and pulmonary comorbidities may play an important role in cytokine release syndrome (CRS) risk in patients with diffuse large B-cell lymphoma (DLBCL).
Real-world data suggest that common cardiac and pulmonary comorbidities may play an important role in cytokine release syndrome (CRS) risk in patients with diffuse large B-cell lymphoma (DLBCL).
Real-world data suggest that...
06/11/2026
Journal of Clinical Pathways

Newsfeed

News
Liquid Biopsies Show Promise but Face Key Challenges in Older Adults
04/29/2026
Lisa Kuhns, PhD, MD
Liquid biopsies hold promise for transforming cancer care in older adults—but age-related biological changes may complicate their accuracy and clinical use.
Liquid biopsies hold promise for transforming cancer care in older adults—but age-related biological changes may complicate their accuracy and clinical use.
Liquid biopsies hold promise for...
04/29/2026
Journal of Clinical Pathways
News
Pharmacist Interventions in The US Oncology Network Cut Cancer Care Costs by Nearly $9 Million
11/17/2025
Grace Taylor, MS, MA
Pharmacist-led interventions within The US Oncology Network cut nearly $9 million in cancer care costs, showcasing the power of targeted medication management in value-based oncology care.
Pharmacist-led interventions within The US Oncology Network cut nearly $9 million in cancer care costs, showcasing the power of targeted medication management in value-based oncology care.
Pharmacist-led interventions...
11/17/2025
Journal of Clinical Pathways
Conference Coverage
Patient-Centered Insights into Treatment Preferences for Locally Advanced and Metastatic NSCLC
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
News
Radiomics and AI Advance NSCLC Staging Precision
03/10/2025
Juliet Gallagher
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.
A recent study published in...
03/10/2025
Journal of Clinical Pathways
News
Machine Learning Identifies Key Genomic Markers to Predict CPI Outcomes in NSCLC
03/06/2025
Grace Taylor, MS, MA
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...
A machine learning-driven study...
03/06/2025
Journal of Clinical Pathways
News
Evaluating Cost-Effectiveness of First-Line Cemiplimab Therapy in Advanced NSCLC
03/05/2025
Juliet Gallagher
A recent cost-effectiveness analysis published in Journal of Managed Care & Specialty Pharmacy comparing cemiplimab plus chemotherapy (CCT) with pembrolizumab plus chemotherapy (PCT) as first-line treatment for advanced non-small cell lung...
A recent cost-effectiveness analysis published in Journal of Managed Care & Specialty Pharmacy comparing cemiplimab plus chemotherapy (CCT) with pembrolizumab plus chemotherapy (PCT) as first-line treatment for advanced non-small cell lung...
A recent cost-effectiveness...
03/05/2025
Journal of Clinical Pathways
News
Durvalumab Immunotherapy Shows Survival Benefit but Fails Cost-Effectiveness in Key Markets
02/13/2025
Lisa Kuhns, PhD, MD
Durvalumab immunotherapy improves survival in unresectable stage III non-small cell lung cancer (NSCLC), but its high cost makes it prohibitive globally under current pricing models, according to study results published in JAMA Network Open.
Durvalumab immunotherapy improves survival in unresectable stage III non-small cell lung cancer (NSCLC), but its high cost makes it prohibitive globally under current pricing models, according to study results published in JAMA Network Open.
Durvalumab immunotherapy...
02/13/2025
Journal of Clinical Pathways
News
Machine Learning Algorithms Offer Alternative to Imaging in NSCLC Staging
02/03/2025
Juliet Gallagher
A recent study published in Journal of Thoracic Disease demonstrated the effectiveness of artificial intelligence (AI) in predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC).
A recent study published in Journal of Thoracic Disease demonstrated the effectiveness of artificial intelligence (AI) in predicting lymph node metastasis in patients with non-small cell lung cancer (NSCLC).
A recent study published in...
02/03/2025
Journal of Clinical Pathways
News
Artificial Intelligence Predicts Survival Outcomes in Advanced NSCLC
01/21/2025
Juliet Gallagher
A recent study published in BMC Cancer developed an artificial intelligence (AI)-based model to predict survival outcomes for patients with advanced non-small cell lung cancer (NSCLC), offering a step forward in personalized medicine.
A recent study published in BMC Cancer developed an artificial intelligence (AI)-based model to predict survival outcomes for patients with advanced non-small cell lung cancer (NSCLC), offering a step forward in personalized medicine.
A recent study published in BMC...
01/21/2025
Journal of Clinical Pathways
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
Stephanie Holland
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
Conference Coverage
Innovations in Relapsed or Refractory Multiple Myeloma Management
09/21/2026
Rebecca Amrick
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, panelists discussed innovations in treating relapsed or refractory multiple myeloma and strategies to improve disease management.
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, panelists discussed innovations in treating relapsed or refractory multiple myeloma and strategies to improve disease management.
At the National Comprehensive...
09/21/2026
Journal of Clinical Pathways
Conference Coverage
Managing Treatment Toxicity Among Patients With Chronic Myeloid Lymphoma
09/21/2026
Rebecca Amrick
Jenna Moran, MSN, FNP-BC, outlined strategies for managing tyrosine kinase inhibitor–related toxicities in patients with chronic myeloid leukemia during a session at the National Comprehensive Cancer Network 2026 Annual Congress.
Jenna Moran, MSN, FNP-BC, outlined strategies for managing tyrosine kinase inhibitor–related toxicities in patients with chronic myeloid leukemia during a session at the National Comprehensive Cancer Network 2026 Annual Congress.
Jenna Moran, MSN, FNP-BC,...
09/21/2026
Journal of Clinical Pathways
Conference Coverage
De-Escalating TKI Therapy Based on Risk and Response for Patients With CML
09/18/2026
Rebecca Amrick
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, Vivian G. Oehler, MD, shared insights on de-escalating tyrosine kinase inhibitor (TKI) therapy among patients with chronic myeloid leukemia (CML)...
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, Vivian G. Oehler, MD, shared insights on de-escalating tyrosine kinase inhibitor (TKI) therapy among patients with chronic myeloid leukemia (CML)...
At the National Comprehensive...
09/18/2026
Journal of Clinical Pathways
News
Anemia Associated With Higher Mortality and AML Transformation Risk in Myelofibrosis
09/17/2026
Rebecca Amrick
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the presence of anemia is likely to increase the risk of mortality and acute myeloid leukemia (AML) transformation among patients with myelofibrosis, indicating anemia as a potential prognostic marker.
Researchers found that the...
09/17/2026
Journal of Clinical Pathways
News
Enhanced Financial Assistance Associated With Improved Radiotherapy Completion
09/08/2026
Rebecca Amrick
Researchers found that providing financial assistance for cancer patients with unmet social needs was associated with improvements in radiotherapy completion, indicating a potential strategy to promote health equity and reduce care gaps.
Researchers found that providing financial assistance for cancer patients with unmet social needs was associated with improvements in radiotherapy completion, indicating a potential strategy to promote health equity and reduce care gaps.
Researchers found that providing...
09/08/2026
Journal of Clinical Pathways
News
Molecular Testing Improves Survival Outcomes for Patients With Endometrial Cancer, Study Finds
09/03/2026
Rebecca Amrick
Researchers found that testing for molecular biomarkers in patients with endometrial cancer is associated with prolonged survival and lower incremental costs than no testing, illustrating the importance of molecular classification in...
Researchers found that testing for molecular biomarkers in patients with endometrial cancer is associated with prolonged survival and lower incremental costs than no testing, illustrating the importance of molecular classification in...
Researchers found that testing...
09/03/2026
Journal of Clinical Pathways
News
Rituximab Biosimilars Demonstrate Clinical Efficiency and Significant Cost Savings Among Patients With NHL and CLL
08/31/2026
Rebecca Amrick
Researchers found that rituximab biosimilars were associated with similar health outcomes and lower care costs than originator rituximab when used to treat patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Researchers found that rituximab biosimilars were associated with similar health outcomes and lower care costs than originator rituximab when used to treat patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Researchers found that rituximab...
08/31/2026
Journal of Clinical Pathways
News
Initiation of Bispecific Antibodies Associated With High Care Costs for Patients With MM
08/24/2026
Rebecca Amrick
A study found that longer hospitalizations were associated with higher care costs among patients with MM initiating treatment with bispecific antibodies, raising concerns about care delivery and access.
A study found that longer hospitalizations were associated with higher care costs among patients with MM initiating treatment with bispecific antibodies, raising concerns about care delivery and access.
A study found that longer...
08/24/2026
Journal of Clinical Pathways
News
Cytopenia Associated With Worse Survival Outcomes in Patients With Myelofibrosis
08/17/2026
Rebecca Amrick
A study found that the presence of cytopenia was associated with poor survival outcomes in patients with myelofibrosis, suggesting cytopenia as a prognostic marker to monitor during disease management.
A study found that the presence of cytopenia was associated with poor survival outcomes in patients with myelofibrosis, suggesting cytopenia as a prognostic marker to monitor during disease management.
A study found that the presence...
08/17/2026
Journal of Clinical Pathways
News
The Impact of Interventions on Serious Illness Conversations
08/14/2026
Rebecca Amrick
Researchers found that intervention strategies focused on clinician reminders could increase rates of serious illness conversations among patients with projected poor health outcomes.
Researchers found that intervention strategies focused on clinician reminders could increase rates of serious illness conversations among patients with projected poor health outcomes.
Researchers found that...
08/14/2026
Journal of Clinical Pathways

Interactive Features

Conference Coverage
Patient-Centered Insights into Treatment Preferences for Locally Advanced and Metastatic NSCLC
03/28/2025
Juliet Gallagher
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the 2025 National Comprehensive Cancer Network (NCCN) Annual Conference sheds light on how patients with advanced or metastatic non-small cell lung cancer (aNSCLC or mNSCLC) approach treatment decision-making,...
New research presented at the...
03/28/2025
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024
Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
News
Tracking Cost of Care Discussions Between Physicians and Patients with NSCLC and Melanoma
10/30/2023
Grace Taylor, MS, MA
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and...
10/30/2023
Journal of Clinical Pathways
News
New Dimensions in Comprehensive Genomic Testing
10/17/2023
Grace Taylor, MS, MA
Eric Severson, MD, PhD, Labcorp Oncology, examines genomic testing’s role in comprehensive oncology pathways.
Eric Severson, MD, PhD, Labcorp Oncology, examines genomic testing’s role in comprehensive oncology pathways.
Eric Severson, MD, PhD, Labcorp...
10/17/2023
Journal of Clinical Pathways
Conference Coverage
Research Shows that Health Care Costs Vary Based on HIC Status in Patients With NSCLC
06/13/2023
Emry Lloyd
In an abstract presented at ASCO 2023, researchers compared real-world data on health care costs for HIC-H and HIC-C patients with NSCLC before and after they received the HIC test.
In an abstract presented at ASCO 2023, researchers compared real-world data on health care costs for HIC-H and HIC-C patients with NSCLC before and after they received the HIC test.
In an abstract presented at ASCO...
06/13/2023
Journal of Clinical Pathways
Gregory Vidal, MD, Phd
Conference Coverage
Inequities in Next-Generation Sequencing Testing Among Patients With Advanced Non–Small Cell Lung Cancer
06/07/2023
Dr Gregory Vidal, Breast Medical Oncologist, West Cancer Center, Germantown, TN, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about his study on inequities in next-generation sequencing testing by race/ethnicity...
Dr Gregory Vidal, Breast Medical Oncologist, West Cancer Center, Germantown, TN, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about his study on inequities in next-generation sequencing testing by race/ethnicity...
Dr Gregory Vidal, Breast Medical...
06/07/2023
Journal of Clinical Pathways
Conference Coverage
Improving Survival and Managing Costs in NSCLC Using Clinical Care Pathways
10/01/2021
Marta Rybczynski
Mark Socinski, MD, discussed the current and ever-evolving treatment landscape of NSCLC and the development and implementation of optimal clinical pathways in this complex disease.
Mark Socinski, MD, discussed the current and ever-evolving treatment landscape of NSCLC and the development and implementation of optimal clinical pathways in this complex disease.
Mark Socinski, MD, discussed the...
10/01/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Adjuvant Osimertinib vs Placebo in NSCLC
06/02/2021
Study findings suggest adjuvant osimertinib is more cost-effective than placebo if one is willing to pay $317,119 more per QALY gained.
Study findings suggest adjuvant osimertinib is more cost-effective than placebo if one is willing to pay $317,119 more per QALY gained.
Study findings suggest adjuvant...
06/02/2021
Journal of Clinical Pathways
Conference Coverage
Treatment Patterns After EGFR-TKI and Platinum-Based Chemotherapy Discontinuation in Metastatic NSCLC
04/16/2021
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
Study results show that...
04/16/2021
Journal of Clinical Pathways
Conference Coverage
Biomarker Testing-Guided Treatment Improves Outcomes in Advanced or Metastatic NSCLC
04/07/2021
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or metastatic NSCLC.
Treatment guided by biomarker...
04/07/2021
Journal of Clinical Pathways
Conference Coverage
Innovations in Relapsed or Refractory Multiple Myeloma Management
09/21/2026
Rebecca Amrick
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, panelists discussed innovations in treating relapsed or refractory multiple myeloma and strategies to improve disease management.
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, panelists discussed innovations in treating relapsed or refractory multiple myeloma and strategies to improve disease management.
At the National Comprehensive...
09/21/2026
Journal of Clinical Pathways
Conference Coverage
Managing Treatment Toxicity Among Patients With Chronic Myeloid Lymphoma
09/21/2026
Rebecca Amrick
Jenna Moran, MSN, FNP-BC, outlined strategies for managing tyrosine kinase inhibitor–related toxicities in patients with chronic myeloid leukemia during a session at the National Comprehensive Cancer Network 2026 Annual Congress.
Jenna Moran, MSN, FNP-BC, outlined strategies for managing tyrosine kinase inhibitor–related toxicities in patients with chronic myeloid leukemia during a session at the National Comprehensive Cancer Network 2026 Annual Congress.
Jenna Moran, MSN, FNP-BC,...
09/21/2026
Journal of Clinical Pathways
Conference Coverage
De-Escalating TKI Therapy Based on Risk and Response for Patients With CML
09/18/2026
Rebecca Amrick
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, Vivian G. Oehler, MD, shared insights on de-escalating tyrosine kinase inhibitor (TKI) therapy among patients with chronic myeloid leukemia (CML)...
At the National Comprehensive Cancer Network 2026 Annual Congress: Hematologic Malignancies, Vivian G. Oehler, MD, shared insights on de-escalating tyrosine kinase inhibitor (TKI) therapy among patients with chronic myeloid leukemia (CML)...
At the National Comprehensive...
09/18/2026
Journal of Clinical Pathways
Conference Coverage
Using Real-World Data to Improve HRR Testing Rates Among Patients With mCRPC
07/17/2026
Andy Osterland, PharmD, MS
Andy Osterland, PharmD, MS, discusses real-world patterns of homologous recombination repair (HRR) testing among patients with metastatic castration-resistant prostate cancer (mCRPC), identifying gaps in testing rates and patient access.
Andy Osterland, PharmD, MS, discusses real-world patterns of homologous recombination repair (HRR) testing among patients with metastatic castration-resistant prostate cancer (mCRPC), identifying gaps in testing rates and patient access.
Andy Osterland, PharmD, MS,...
07/17/2026
Journal of Clinical Pathways
Jessica Paulus Headshot
Conference Coverage
Distress Thermometer Scores Highlight Association Between Psychosocial Distress and Survival Outcomes for Cancer Patients
07/13/2026
Jessica Paulus, ScD
Jessica Paulus, ScD, discusses the association between psychosocial distress and survival outcomes among patients with breast, colorectal, and lung cancer.
Jessica Paulus, ScD, discusses the association between psychosocial distress and survival outcomes among patients with breast, colorectal, and lung cancer.
Jessica Paulus, ScD, discusses...
07/13/2026
Journal of Clinical Pathways
Jessica Paulus Headshot
Conference Coverage
Closing the Gap Between Clinical Guideline Updates and Real-World Adoption for HER2-Low Therapies
06/17/2026
Jessica Paulus, ScD
Jessica Paulus, ScD, discusses the impact of education on increasing rates of human epidermal growth factor receptor 2 (HER2)-low therapy for patients with metastatic breast cancer.
Jessica Paulus, ScD, discusses the impact of education on increasing rates of human epidermal growth factor receptor 2 (HER2)-low therapy for patients with metastatic breast cancer.
Jessica Paulus, ScD, discusses...
06/17/2026
Journal of Clinical Pathways
Headshot of Dr. Andy Osterland
Conference Coverage
Using Patient Characteristics and Treatment History to Inform Treatment Plans for Patients With Gene-Mutated MCRPC
06/15/2026
Andy Osterland, PharmD, MS
Andy Osterland, PharmD, MS, discusses a real-world study of patients with metastatic castration-resistant prostate cancer (MCRPC) who were treated with talazoparib plus enzalutamide and the regimen’s impact on homologous recombination repair...
Andy Osterland, PharmD, MS, discusses a real-world study of patients with metastatic castration-resistant prostate cancer (MCRPC) who were treated with talazoparib plus enzalutamide and the regimen’s impact on homologous recombination repair...
Andy Osterland, PharmD, MS,...
06/15/2026
Journal of Clinical Pathways
Metastatic Prostate Cancer
Conference Coverage
Closing the Gap in HRR Testing for Metastatic Prostate Cancer in Community Oncology
06/04/2026
Helen Latimer, MPH
Helen Latimer, MPH, discusses new real-world evidence showing increased homologous recombination repair (HRR) genetic testing among patients with metastatic prostate cancer and the potential of electronic health record (HER)-driven clinical...
Helen Latimer, MPH, discusses new real-world evidence showing increased homologous recombination repair (HRR) genetic testing among patients with metastatic prostate cancer and the potential of electronic health record (HER)-driven clinical...
Helen Latimer, MPH, discusses...
06/04/2026
Journal of Clinical Pathways
Conference Coverage
Community-Engaged Strategies Reduce Cancer Care Delays and Advance Health Equity
03/27/2026
Hannah Musick
A nationwide, community-engaged cancer care initiative shows that coordinated workflows, patient navigation, and targeted social determinants of health interventions can improve treatment adherence, patient satisfaction, and equity in access...
A nationwide, community-engaged cancer care initiative shows that coordinated workflows, patient navigation, and targeted social determinants of health interventions can improve treatment adherence, patient satisfaction, and equity in access...
A nationwide, community-engaged...
03/27/2026
Journal of Clinical Pathways
Conference Coverage
Targeted Education Improves Cancer Pain Management in Community Hospitals
03/27/2026
Grace Taylor, MS, MA
A brief, National Comprehensive Cancer Network (NCCN)-guided educational session markedly improved hospitalists’ confidence and evidence-based cancer pain management practices in a community hospital setting.
A brief, National Comprehensive Cancer Network (NCCN)-guided educational session markedly improved hospitalists’ confidence and evidence-based cancer pain management practices in a community hospital setting.
A brief, National Comprehensive...
03/27/2026
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use